Search research articles
Contact Us
Filters
Showing results (131-140 of 145) with videos related to
Page
of 15
Sort By:
JHEP Reports : Innovation in Hepatology
|
February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
The Lancet. Oncology
|
November 11, 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
Qinghe Zeng, Christophe Klein, Stefano Caruso, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 12, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
Ilario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose, et al.
Cancer Cell
|
December 14, 2016
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition
Shigeki Nakagawa, Lan Wei, Won Min Song, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 15, 2020
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Leonardo G da Fonseca, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 24, 2022
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study
Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Liver Cancer
|
September 19, 2024
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Targeted Oncology
|
January 22, 2024
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma
Silvia Camera, Margherita Rimini, Federico Rossari, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 145) with videos related to
Sort By:
Page
of 15
JHEP Reports : Innovation in Hepatology
|
February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
The Lancet. Oncology
|
November 11, 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
Qinghe Zeng, Christophe Klein, Stefano Caruso, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 12, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
Ilario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose, et al.
Cancer Cell
|
December 14, 2016
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition
Shigeki Nakagawa, Lan Wei, Won Min Song, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 15, 2020
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Leonardo G da Fonseca, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 24, 2022
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study
Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Liver Cancer
|
September 19, 2024
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Targeted Oncology
|
January 22, 2024
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma
Silvia Camera, Margherita Rimini, Federico Rossari, et al.
Page
of 15